Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis. Three children, none of whom received prophylaxis, experienced cytomegalovirus reactivation. Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted.

Original languageEnglish
Pages (from-to)323-327
Number of pages5
JournalJournal of Microbiology, Immunology and Infection
Volume55
Issue number2
DOIs
Publication statusPublished - 2022 Apr

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • General Immunology and Microbiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan'. Together they form a unique fingerprint.

Cite this